[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,700,503
  • Shares Outstanding, K 60,981
  • Annual Sales, $ 521,310 K
  • Annual Income, $ -23,360 K
  • EBIT $ -796 M
  • EBITDA $ -770 M
  • 60-Month Beta 0.50
  • Price/Sales 10.82
  • Price/Cash Flow 1,814.27
  • Price/Book 23.26

Options Overview Details

View History
  • Implied Volatility 48.28% (+1.19%)
  • Historical Volatility 56.99%
  • IV Percentile 55%
  • IV Rank 24.12%
  • IV High 99.96% on 04/10/26
  • IV Low 31.86% on 08/21/25
  • Expected Move (DTE 11) 3.41 (3.65%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 60
  • Volume Avg (30-Day) 475
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 2,699
  • Open Int (30-Day) 4,738
  • Expected Range 90.07 to 96.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 6
  • High Estimate $-0.37
  • Low Estimate $-1.47
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -483.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
90.59 +3.19%
on 06/03/26
114.99 -18.71%
on 05/13/26
-12.33 (-11.65%)
since 05/05/26
3-Month
84.33 +10.85%
on 03/09/26
114.99 -18.71%
on 05/13/26
+5.64 (+6.42%)
since 03/05/26
52-Week
45.17 +106.95%
on 06/06/25
114.99 -18.71%
on 05/13/26
+48.83 (+109.36%)
since 06/05/25

Most Recent Stories

More News
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)

MIRM : 93.48 (+1.07%)
INCY : 102.38 (+1.13%)
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) -...

MIRM : 93.48 (+1.07%)
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional...

MIRM : 93.48 (+1.07%)
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) -...

MIRM : 93.48 (+1.07%)
Mirum Pharma: A Rare Disease Growth Story to Watch

Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company

MIRM : 93.48 (+1.07%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on May 11, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting...

MIRM : 93.48 (+1.07%)
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible senior...

MIRM : 93.48 (+1.07%)
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and other factors, $600.0 million aggregate...

MIRM : 93.48 (+1.07%)
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: ...

MIRM : 93.48 (+1.07%)
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

- Q1 2026 net product sales of $159.9 million - 2026 net product sales guidance increased to $660 to $680 million - Volixibat...

MIRM : 93.48 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 96.54
2nd Resistance Point 95.29
1st Resistance Point 94.39
Last Price 93.48
1st Support Level 92.23
2nd Support Level 90.98
3rd Support Level 90.08

See More

52-Week High 114.99
Last Price 93.48
Fibonacci 61.8% 88.32
Fibonacci 50% 80.08
Fibonacci 38.2% 71.84
52-Week Low 45.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.